1. Which intracellular reducing systems carry out the activating reduction of metronidazole's nitro group in susceptible organisms?
A) Hepatic cytochrome P450 mixed-function oxidases
B) Low-potential electron donors such as ferredoxin and pyruvate:ferredoxin oxidoreductase
C) NADPH oxidase of host neutrophils
D) Mitochondrial complex IV (cytochrome c oxidase)
E) Glutathione peroxidase coupled to glutathione reductase
ANSWER: B
Rationale:
In anaerobic and microaerophilic organisms, low-potential electron carriers reduce the metronidazole nitro group to the reactive nitroso radical anion; ferredoxin operates in anaerobic bacteria and Giardia, and pyruvate:ferredoxin oxidoreductase operates in Trichomonas and Entamoeba. These donors are absent from aerobic host cells, which is the basis for selectivity.
Option A: Option A is incorrect: cytochrome P450 contributes to metronidazole elimination, not to the reductive activation that generates the cytotoxic radical.
Option C: Option C is incorrect: host NADPH oxidase produces oxidative radicals for microbial killing and does not reductively activate the drug.
Option D: Option D is incorrect: cytochrome c oxidase is a terminal oxidase of aerobic respiration, not a low-potential reductant for nitro activation.
Option E: Option E is incorrect: the glutathione peroxidase/reductase couple is an antioxidant defense system and does not activate the prodrug.
2. Once metronidazole is reductively activated, what is the principal mechanism by which the reactive intermediate kills the organism?
A) Irreversible inhibition of the 50S ribosomal subunit, halting protein synthesis
B) Inhibition of dihydrofolate reductase, blocking folate-dependent synthesis
C) Disruption of cell wall peptidoglycan cross-linking
D) DNA strand breakage and destabilization of the DNA helix, inhibiting nucleic acid synthesis
E) Inhibition of ergosterol biosynthesis, compromising membrane integrity
ANSWER: D
Rationale:
The reactive nitroso radical anion formed on activation attacks DNA, producing strand breaks and helix destabilization that block nucleic acid synthesis and cause rapid death; the short half-life of the intermediate keeps damage localized to the organism that generated it.
Option A: Option A is incorrect: ribosomal 50S inhibition describes macrolides and related protein-synthesis inhibitors, not metronidazole.
Option B: Option B is incorrect: dihydrofolate reductase inhibition describes pyrimethamine and trimethoprim.
Option C: Option C is incorrect: peptidoglycan cross-link disruption describes beta-lactams and does not apply to protozoa, which lack a bacterial cell wall.
Option E: Option E is incorrect: ergosterol-pathway inhibition describes azole antifungals; metronidazole does not act on sterol synthesis.
3. Which pharmacokinetic property most directly distinguishes tinidazole from metronidazole and enables single-dose therapy for giardiasis and trichomoniasis?
A) A longer elimination half-life of approximately 12 to 14 hours
B) A markedly higher oral bioavailability that metronidazole cannot achieve
C) Activity against aerobic organisms in addition to anaerobes
D) Absence of any disulfiram-like interaction with alcohol
E) A distinct mechanism of action not shared with the nitroimidazole class
ANSWER: A
Rationale:
Tinidazole's longer elimination half-life (about 12 to 14 hours, versus roughly 6 to 10 hours for metronidazole), together with better gastrointestinal tolerability, sustains effective drug exposure from a single dose.
Option B: Option B is incorrect: metronidazole already achieves oral bioavailability above 90 percent, so superior absorption is not the distinguishing feature.
Option C: Option C is incorrect: tinidazole, like metronidazole, acts on anaerobes and microaerophiles, not aerobes.
Option D: Option D is incorrect: tinidazole also causes a disulfiram-like reaction, and the alcohol-avoidance interval is actually longer because of its longer half-life.
Option E: Option E is incorrect: tinidazole is a nitroimidazole and shares the reductive-activation mechanism of the class.
4. The disulfiram-like reaction provoked by alcohol during metronidazole therapy results from inhibition of which enzyme?
A) Alcohol dehydrogenase, blocking conversion of ethanol to acetaldehyde
B) Cytochrome P450 2E1, the inducible ethanol-oxidizing isoform
C) Acetaldehyde dehydrogenase, causing acetaldehyde to accumulate
D) Monoamine oxidase, causing accumulation of dietary amines
Metronidazole inhibits acetaldehyde dehydrogenase, the enzyme that clears acetaldehyde generated from ethanol. Acetaldehyde then accumulates and produces flushing, nausea, vomiting, headache, and tachycardia, the disulfiram-like reaction.
Option A: Option A is incorrect: inhibiting alcohol dehydrogenase would reduce acetaldehyde formation, the opposite of what occurs.
Option B: Option B is incorrect: the reaction is driven by impaired acetaldehyde clearance, not by altered cytochrome P450 2E1 activity.
Option D: Option D is incorrect: monoamine oxidase inhibition underlies the tyramine reaction with monoamine oxidase inhibitors, a different mechanism.
Option E: Option E is incorrect: aldehyde reductase is not the locus of this interaction, and the accumulating species is acetaldehyde, not ethanol.
5. For which indication is suramin the appropriate agent?
A) Stage 2 (encephalitic) Trypanosoma brucei gambiense infection
B) Stage 2 (encephalitic) Trypanosoma brucei rhodesiense infection
C) Chronic Chagas cardiomyopathy due to Trypanosoma cruzi
D) Visceral leishmaniasis due to Leishmania donovani
Suramin does not cross the blood-brain barrier, so its use is confined to stage 1 (hemolymphatic) disease, and it is the agent of choice for stage 1 Trypanosoma brucei rhodesiense.
Option A: Option A is incorrect: stage 2 gambiense disease requires a central-nervous-system-penetrating regimen such as the nifurtimox-eflornithine combination, not suramin.
Option B: Option B is incorrect: stage 2 rhodesiense disease requires melarsoprol, since suramin cannot reach the central nervous system.
Option C: Option C is incorrect: Chagas disease is treated with benznidazole or nifurtimox, not suramin.
Option D: Option D is incorrect: visceral leishmaniasis is treated with liposomal amphotericin B or miltefosine, not suramin.
6. Pentamidine is the preferred agent for which stage and subspecies of human African trypanosomiasis?
A) Stage 2 Trypanosoma brucei rhodesiense
B) Stage 1 Trypanosoma brucei gambiense
C) Stage 1 Trypanosoma brucei rhodesiense
D) Stage 2 Trypanosoma brucei gambiense
E) Both stages of Trypanosoma brucei rhodesiense
ANSWER: B
Rationale:
Pentamidine is preferred for stage 1 Trypanosoma brucei gambiense, while suramin is reserved for stage 1 Trypanosoma brucei rhodesiense; the two stage 1 agents are assigned by subspecies based on differential susceptibility.
Option A: Option A is incorrect: stage 2 rhodesiense requires melarsoprol.
Option C: Option C is incorrect: stage 1 rhodesiense is treated with suramin, not pentamidine.
Option D: Option D is incorrect: stage 2 gambiense requires a central-nervous-system-penetrating regimen such as the nifurtimox-eflornithine combination.
Option E: Option E is incorrect: pentamidine does not cover stage 2 disease of either subspecies, as it does not reliably treat established central nervous system infection.
7. Melarsoprol exerts its trypanocidal effect primarily through which molecular interaction?
A) Its trivalent arsenic moiety reacts with trypanothione and inhibits trypanothione reductase, disrupting parasite redox homeostasis
B) It intercalates kinetoplast DNA and collapses the mitochondrial membrane potential
C) It irreversibly inhibits ornithine decarboxylase, halting polyamine synthesis
D) It binds ergosterol-like membrane sterols, causing lethal ion flux
E) It inhibits dihydrofolate reductase, blocking tetrahydrofolate regeneration
ANSWER: A
Rationale:
Melarsoprol is an organoarsenical whose trivalent arsenic reacts with trypanothione (the parasite-specific glutathione-spermidine conjugate) and inhibits trypanothione reductase, collapsing the redox defenses that the parasite depends on.
Option B: Option B is incorrect: kinetoplast DNA binding with loss of mitochondrial membrane potential describes pentamidine.
Option C: Option C is incorrect: irreversible ornithine decarboxylase inhibition describes eflornithine.
Option D: Option D is incorrect: binding ergosterol-like sterols describes amphotericin B.
Option E: Option E is incorrect: dihydrofolate reductase inhibition describes pyrimethamine.
8. Which adverse reaction is the most feared, treatment-limiting toxicity of melarsoprol?
A) Irreversible high-frequency sensorineural hearing loss
B) Pancreatitis progressing to hemorrhagic necrosis
C) Post-treatment reactive encephalopathy, an inflammatory syndrome fatal in roughly half of those affected
D) Profound hypoglycemia from pancreatic beta-cell injury
E) QTc prolongation with torsades de pointes
ANSWER: C
Rationale:
Melarsoprol causes post-treatment reactive encephalopathy in about 5 to 10 percent of treated patients; the syndrome is fatal in roughly half of those affected, producing an overall treatment-attributable mortality of about 2 to 5 percent, and concurrent prednisolone reduces but does not eliminate the risk.
Option A: Option A is incorrect: ototoxicity is characteristic of aminoglycosides, not melarsoprol.
Option B: Option B is incorrect: pancreatitis is a leading toxicity of pentavalent antimonials.
Option D: Option D is incorrect: hypoglycemia from beta-cell injury is characteristic of pentamidine.
Option E: Option E is incorrect: QTc prolongation with torsades de pointes is a recognized risk of pentavalent antimonials, not melarsoprol.
9. Eflornithine (difluoromethylornithine) treats Trypanosoma brucei gambiense by inhibiting which enzyme?
A) Trypanothione reductase, the parasite redox-maintenance enzyme
B) Dihydropteroate synthase, an early folate-synthesis enzyme
C) Pyruvate:ferredoxin oxidoreductase, a low-potential electron donor
D) Ornithine decarboxylase, the rate-limiting enzyme of polyamine biosynthesis
E) Topoisomerase II, required for kinetoplast DNA replication
ANSWER: D
Rationale:
Eflornithine is an irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme of polyamine biosynthesis; polyamines (putrescine, spermidine, spermine) are essential for trypanosome division, and gambiense is susceptible because it turns the enzyme over slowly.
Option A: Option A is incorrect: trypanothione reductase is the target of melarsoprol and the antimonials, not eflornithine.
Option B: Option B is incorrect: dihydropteroate synthase is inhibited by sulfonamides such as sulfadiazine.
Option C: Option C is incorrect: pyruvate:ferredoxin oxidoreductase is the activator of metronidazole, not an eflornithine target.
Option E: Option E is incorrect: eflornithine does not act on topoisomerase II.
10. Which statement correctly characterizes benznidazole?
A) It is a polysulfonated naphthylurea that does not cross the blood-brain barrier
B) It is an organoarsenical reserved for stage 2 sleeping sickness
C) It is an alkylphosphocholine and the first oral agent for visceral leishmaniasis
D) It is a pentavalent antimony compound requiring intracellular reduction to the trivalent form
E) It is a nitroimidazole derivative activated by Trypanosoma cruzi nitroreductases and is first-line for Chagas disease
ANSWER: E
Rationale:
Benznidazole is a nitroimidazole derivative that undergoes reductive activation by Trypanosoma cruzi nitroreductases to generate reactive intermediates that damage parasite DNA, proteins, and lipids; it is the first-line agent for Chagas disease worldwide.
Option A: Option A is incorrect: a polysulfonated naphthylurea that does not cross the blood-brain barrier describes suramin.
Option B: Option B is incorrect: an organoarsenical for stage 2 sleeping sickness describes melarsoprol.
Option C: Option C is incorrect: an alkylphosphocholine and first oral visceral leishmaniasis agent describes miltefosine.
Option D: Option D is incorrect: a pentavalent antimony compound reduced to the trivalent form describes sodium stibogluconate and meglumine antimoniate.
11. By what mechanism does nifurtimox kill Trypanosoma cruzi?
A) Irreversible inhibition of ornithine decarboxylase, depleting polyamines
B) One-electron reduction generating superoxide and other reactive oxygen species that overwhelm the parasite trypanothione defense
C) Binding to ergosterol-like sterols, producing membrane ion leakage
D) Sequential blockade of dihydropteroate synthase and dihydrofolate reductase
E) Inhibition of the 30S ribosomal subunit, halting protein synthesis
ANSWER: B
Rationale:
Nifurtimox is a nitrofuran that undergoes one-electron reduction to generate superoxide and other reactive oxygen species; because trypanosomes rely on the trypanothione system rather than a robust catalase/glutathione defense, this oxidative burst overwhelms their antioxidant capacity.
Option A: Option A is incorrect: ornithine decarboxylase inhibition describes eflornithine.
Option C: Option C is incorrect: ergosterol-like sterol binding describes amphotericin B.
Option D: Option D is incorrect: sequential folate-pathway blockade describes pyrimethamine plus a sulfonamide.
Option E: Option E is incorrect: 30S ribosomal inhibition describes aminoglycosides and tetracyclines, not nifurtimox.
12. What is the leishmanicidal mechanism of liposomal amphotericin B?
A) Reductive activation generating DNA-damaging radical anions
B) Inhibition of trypanothione reductase after intracellular reduction
C) Binding to ergosterol-like membrane sterols, disrupting membrane integrity and causing lethal ion flux
D) Irreversible inhibition of ornithine decarboxylase
E) Accumulation in the kinetoplast with disruption of kinetoplast DNA
ANSWER: C
Rationale:
Amphotericin B binds the ergosterol-like sterols of the Leishmania membrane, disrupts membrane integrity, and causes lethal ion flux; the liposomal formulation concentrates in the reticuloendothelial system, where amastigotes reside within macrophages, while limiting nephrotoxicity.
Option A: Option A is incorrect: reductive activation to radical anions describes the nitroimidazoles.
Option B: Option B is incorrect: trypanothione reductase inhibition describes melarsoprol and the antimonials.
Option D: Option D is incorrect: ornithine decarboxylase inhibition describes eflornithine.
Option E: Option E is incorrect: kinetoplast DNA disruption describes pentamidine.
13. Which description correctly identifies miltefosine?
A) An alkylphosphocholine that is the first oral agent effective against visceral leishmaniasis and is teratogenic
B) A pentavalent antimonial requiring parenteral administration for 28 days
C) A diamidine that accumulates in the parasite kinetoplast
D) An organoarsenical used for stage 2 sleeping sickness
E) A polyene that binds membrane sterols of the parasite
ANSWER: A
Rationale:
Miltefosine is an alkylphosphocholine, originally developed as an anticancer agent, that disrupts Leishmania membrane phospholipid composition and ether-lipid metabolism; it was the first oral agent with proven efficacy against visceral leishmaniasis and is teratogenic (Category X) with a long half-life requiring 5 months of contraception afterward.
Option B: Option B is incorrect: a parenteral antimonial describes sodium stibogluconate or meglumine antimoniate.
Option C: Option C is incorrect: a diamidine accumulating in the kinetoplast describes pentamidine.
Option D: Option D is incorrect: an organoarsenical for stage 2 sleeping sickness describes melarsoprol.
Option E: Option E is incorrect: a polyene binding membrane sterols describes amphotericin B.
14. Pentavalent antimonials (sodium stibogluconate, meglumine antimoniate) require which step to become active against Leishmania?
A) Glucuronide conjugation in the hepatocyte before biliary excretion
B) One-electron reduction generating reactive oxygen species in the cytosol
C) Demethylation by parasite cytochrome P450 to an active phenol
D) Intracellular reduction from the pentavalent form (Sb(V)) to the active trivalent form (Sb(III)) within macrophage phagolysosomes
E) Hydrolysis by plasma esterases to liberate free antimony ion
ANSWER: D
Rationale:
Pentavalent antimony (Sb(V)) is a prodrug form that must be reduced to the trivalent species (Sb(III)) inside macrophage phagolysosomes, where Sb(III) inhibits trypanothione reductase and disrupts parasite energy metabolism.
Option A: Option A is incorrect: glucuronidation is an elimination pathway, not an activating reduction.
Option B: Option B is incorrect: one-electron reduction to reactive oxygen species describes nifurtimox activation.
Option C: Option C is incorrect: antimonials are not activated by cytochrome P450 demethylation.
Option E: Option E is incorrect: activation is intracellular reduction, not plasma ester hydrolysis.
15. In the pyrimethamine-sulfadiazine regimen for toxoplasmosis, which pairing of drug to enzyme target is correct?
A) Pyrimethamine inhibits dihydropteroate synthase; sulfadiazine inhibits dihydrofolate reductase
B) Both drugs inhibit dihydrofolate reductase at different binding sites
C) Pyrimethamine inhibits thymidylate synthase; sulfadiazine inhibits dihydrofolate reductase
D) Both drugs inhibit dihydropteroate synthase competitively with para-aminobenzoic acid
The regimen produces sequential blockade of folate synthesis: sulfadiazine, a sulfonamide, competitively inhibits dihydropteroate synthase (an early step converting para-aminobenzoic acid to dihydropteroate), and pyrimethamine inhibits dihydrofolate reductase (the downstream step generating tetrahydrofolate).
Option A: Option A reverses the two assignments.
Option B: Option B is incorrect: only pyrimethamine acts on dihydrofolate reductase; sulfadiazine acts upstream.
Option C: Option C is incorrect: pyrimethamine targets dihydrofolate reductase, not thymidylate synthase.
Option D: Option D is incorrect: only the sulfonamide competes with para-aminobenzoic acid at dihydropteroate synthase; pyrimethamine acts downstream.
16. What is the role of spiramycin in the management of toxoplasmosis acquired during pregnancy?
A) It is the definitive treatment for established fetal infection, achieving fetal cure
B) It is the preferred agent for toxoplasmic encephalitis in adults with AIDS
C) It concentrates in placental tissue and reduces vertical (mother-to-fetus) transmission but does not treat established fetal infection
D) It provides secondary prophylaxis against reactivation until immune reconstitution
E) It replaces folinic acid as the marrow-protective agent in pyrimethamine regimens
ANSWER: C
Rationale:
Spiramycin concentrates in placental tissue and is used during pregnancy to reduce the risk of vertical transmission; because it does not reliably cross to treat infection already established in the fetus, confirmed fetal infection is instead managed with pyrimethamine-sulfadiazine-folinic acid.
Option A: Option A is incorrect: spiramycin does not achieve fetal cure of established infection.
Option B: Option B is incorrect: toxoplasmic encephalitis is treated with pyrimethamine-sulfadiazine-folinic acid, not spiramycin.
Option D: Option D is incorrect: secondary prophylaxis uses reduced-dose pyrimethamine-sulfadiazine-folinic acid, not spiramycin.
Option E: Option E is incorrect: folinic acid is the marrow-protective agent and is not replaced by spiramycin.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.